Fresenius Kabi AG

Fresenius Kabi AG is a German healthcare company and a subsidiary of Fresenius SE & Co. KGaA, specializing in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. Founded in 1912 and headquartered in Bad Homburg, Germany, Fresenius Kabi has evolved into a global leader in healthcare with operations spanning over 100 countries. The company focuses on three core business segments: Clinical Nutrition, which provides specialized nutritional products for critically ill patients; Biopharma, which develops and manufactures biosimilars and biopharmaceuticals; and MedTech, which offers medical devices and technologies for medication management and infusion therapy. Fresenius Kabi operates more than 40 production sites worldwide and maintains one of the industry's most comprehensive portfolios of generic IV drugs, biosimilars, and clinical nutrition products. The company serves hospitals, healthcare providers, and patients across acute care settings, with particular strength in critical care, oncology, and specialized therapeutic areas. With over 40,000 employees globally, Fresenius Kabi invests significantly in research and development, manufacturing excellence, and quality assurance to ensure the highest standards of patient safety. The company has established strategic partnerships and joint ventures to expand its global reach and enhance its product portfolio, particularly in emerging markets and biosimilar development. Fresenius Kabi is recognized for its commitment to improving patient outcomes through innovative healthcare solutions and sustainable business practices.